Donald E. Bobo Jr. - 08 Mar 2023 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Signature
Linda J. Park, Attorney-in-Fact
Issuer symbol
EW
Transactions as of
08 Mar 2023
Net transactions value
-$280,860
Form type
4
Filing time
08 Mar 2023, 16:56:04 UTC
Previous filing
06 Feb 2023
Next filing
06 Apr 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $236,698 +6,725 +11% $35.20 69,286 08 Mar 2023 Direct F1
transaction EW Common Stock Sale $517,558 -6,725 -9.7% $76.96 62,561 08 Mar 2023 Direct F1, F2
holding EW Common Stock 38,314 08 Mar 2023 401(k) F3
holding EW Common Stock 117,320 08 Mar 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -6,725 -50% $0.000000 6,725 08 Mar 2023 Common Stock 6,725 $35.20 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 25, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $76.40 to $77.37 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
F3 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.